Skip to content
Screener

Wave Life Sciences WVE Retained Earnings

Retained Earnings at other companies

Eli Lilly logo
Eli LillyLLY
$31.89B+83.5%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$4.55B-2.0%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$2.84B-24.9%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
-$2.24B-17.0%
ALN
Alnylam PharmaceuticalsALNY
-$6.33B+14.6%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$1.74B-3.6%

Other financials

Income statement

See full
Revenue$2.3M-73.9%
Operating income-$73.8M-39.9%
Net income-$69.4M-37.4%
EPS (diluted)-$0.34-9.7%

Balance sheet

See full
Cash & equivalents$368.0M+76.5%
Total debt$43.6M+101%
Total equity$453.5M+226%
Total assets$558.3M+121%

Cash flow

See full
Operating cash flow-$53.6M-16.5%
CapEx$884.0K+189%
Free cash flow-$54.5M-17.6%

Valuation

See full
Market cap$1.2B-7.3%
Enterprise value$877.58M-21.0%
P/S20.6×-16.6×

Profitability

See full
Operating margin-75.7%-33.6pp
Net margin-66.5%-29.9pp
FCF margin-27.2%-12.6pp

Returns & leverage

See full
Return on equity-68.3%
Debt / equity0.1×-0.1×
Current ratio10×+7.4×

Where this comes from

Reported directly by Wave Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 7:50 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324949
Line itemJune 30, 2026December 31, 2025
Series A preferred shares, no par value; nil and 3,901,348 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively$7,874
Shareholders’ equity:
Ordinary shares, no par value; 193,277,622 and 187,660,263 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively$1,627,209$1,616,478
Additional paid-in capital248,161228,365
Accumulated other comprehensive loss(172)(250)
Accumulated deficit(1,421,678)(1,326,236)
Total shareholders’ equity$453,520$518,357
Total liabilities, Series A preferred shares, and shareholders’ equity$558,321$638,499

Item 1. Financial Statements

FAQ

What is Wave Life Sciences's retained earnings?
Wave Life Sciences (WVE) reported retained earnings of -$1.42B in Q2 2026.
How has Wave Life Sciences's retained earnings changed year-over-year?
Wave Life Sciences's retained earnings decreased by 16.6% year-over-year, from -$1.22B to -$1.42B.
What is the long-term trend for Wave Life Sciences's retained earnings?
Over 5 years (2020 to 2025), Wave Life Sciences's retained earnings has grown at a 14.2% compound annual growth rate (CAGR), from -$683.27M to -$1.33B.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about Wave Life Sciences's retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude